) Recent evidence has established the importance of the alpha v Beta 3 and alpha v Beta 5 integrins and their interaction with matrix in tumor-induced angiogenesis. High-risk neuroblastoma is associated with active angiogenesis, suggesting that integrins and matrix degrading proteases play a role in this disease. We recently showed that ceramide, a lipid second messenger important in apoptosis, increases in endothelial cells following inhibition of integrin alpha v Beta 3- and alpha v Beta 5-mediated anchorage. The goals of this project are to define the potential of alpha v Beta 3 and/or alpha v Beta 5 and their interaction with proteolyzed collagen as targets for anti-angiogenic treatment in neuroblastoma and to improve the efficacy of this anti-angiogenic approach by combining it with modifiers of intracellular ceramide metabolism. Our preliminary data supports the following hypothesis: (1) antagonism of integrins alpha v Beta 3 and alpha v Beta 5, which are potentially important to neuroblastoma angiogenesis, will provide a mechanism for attack of tumor endothelium and improve treatment of high-risk neuroblastoma; (2) manipulation of signaling pathways to increase endogenous endothelial ceramide and/or inactivate survival kinases will enhance the anti-angiogenic response of neuroblastoma. Our work will consist of three Specific Aims: (1) to define the angiogenic phenotype of primary untreated neuroblastomas with regard to expression of alpha v Beta 3, alpha v Beta 5, proteolyzed collagen, MMP-9 and PAI-1 using immunohistochemistry; (2) to analyze endothelial signaling pathways regulated by ceramide under conditions of anoikis induced by antagonism of alpha v Beta 3 or alpha v Beta 5 integrins and/or ceramide challenge; (3) to use alpha v Beta 3 and alpha v Beta 5 antagonists and agents which interfere with ceramide-regulated pathways in in vivo models for local and metastatic neuroblastoma to determine which individual or synergistic antitumor effects. Research Design: The feasibility of treating neuroblastoma with anti-angiogenic treatments directed against integrin alpha v Beta 3 and alpha v Beta 5 or direct antagonism of proteolyzed type V collagen will be examined using in vivo and in vitro models. The signal transduction pathways regulated by ceramide that function in endothelial anoikis will be identified using experiments in cell culture. This integrated approach will likely yield novel therapeutic agents for the treatment of neuroblastoma and other tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA081403-01A1
Application #
6404038
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2000-07-06
Project End
2005-05-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Children's Hospital of Los Angeles
Department
Type
DUNS #
094878337
City
Los Angeles
State
CA
Country
United States
Zip Code
90027
Pinto, Navin; DuBois, Steven G; Marachelian, Araz et al. (2018) Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatr Blood Cancer 65:e27023
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Villablanca, Judith G; Ji, Lingyun; Shapira-Lewinson, Adi et al. (2018) Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma. Pediatr Blood Cancer 65:e26940
Niemas-Teshiba, Risa; Matsuno, Ryosuke; Wang, Larry L et al. (2018) MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget 9:6416-6432
Webb, Matthew W; Sun, Jianping; Sheard, Michael A et al. (2018) Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes. Int J Cancer 143:1483-1493
Cho, Hwang Eui; Min, H Kang (2017) Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics. J Pharm Biomed Anal 132:117-124
Zheng, Tina; Ménard, Marie; Weiss, William A (2017) Neuroblastoma Metastases: Leveraging the Avian Neural Crest. Cancer Cell 32:395-397
Erdreich-Epstein, Anat; Singh, Alok R; Joshi, Shweta et al. (2017) Association of high microvessel ?v?3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget 8:52193-52210
Marachelian, Araz; Villablanca, Judith G; Liu, Cathy W et al. (2017) Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. Clin Cancer Res 23:5374-5383
Borriello, Lucia; Nakata, Rie; Sheard, Michael A et al. (2017) Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. Cancer Res 77:5142-5157

Showing the most recent 10 out of 150 publications